XJPX4576
Market cap34mUSD
Jan 09, Last price
170.00JPY
1D
0.59%
1Q
139.44%
Jan 2017
-58.33%
IPO
-60.28%
Name
D.Western Therapeutics Institute Inc
Chart & Performance
P/E
—
P/S
12.59
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
56.51%
Revenues
428m
-4.40%
Net income
-812m
L+89.07%
CFO
-587m
L+65.41%
Profile
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 428,364 -4.40% | 448,100 8.13% | |||
Cost of revenue | 1,225,172 | 752,130 | |||
Unusual Expense (Income) | |||||
NOPBT | (796,808) | (304,030) | |||
NOPBT Margin | |||||
Operating Taxes | 1,595 | 1,595 | |||
Tax Rate | |||||
NOPAT | (798,403) | (305,625) | |||
Net income | (812,411) 89.07% | (429,685) 188.39% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 88,994 | 86,381 | |||
BB yield | -1.99% | -1.11% | |||
| Debt | |||||
Debt current | 9,524 | 120,000 | |||
Long-term debt | 875,598 | 847,693 | |||
Deferred revenue | |||||
Other long-term liabilities | 24,000 | 24,001 | |||
Net debt | (1,120,142) | (1,528,975) | |||
| Cash flow | |||||
Cash from operating activities | (586,821) | (354,770) | |||
CAPEX | (14,938) | (9,814) | |||
Cash from investing activities | (15,254) | (139,890) | |||
Cash from financing activities | 134,466 | 867,297 | |||
FCF | (663,030) | (379,641) | |||
| Balance | |||||
Cash | 1,867,264 | 2,334,668 | |||
Long term investments | 138,000 | 162,000 | |||
Excess cash | 1,983,846 | 2,474,263 | |||
Stockholders' equity | (1,610,755) | (899,730) | |||
Invested Capital | 3,799,642 | 3,753,665 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 31,780 | 29,640 | |||
Price | 141.00 -46.18% | 262.00 21.30% | |||
Market cap | 4,480,989 -42.30% | 7,765,657 22.56% | |||
EV | 3,360,847 | 6,253,669 | |||
EBITDA | (748,087) | (257,664) | |||
EV/EBITDA | |||||
Interest | 2,490 | 3,147 | |||
Interest/NOPBT | |||||